Analysts are projecting that Merck & Company, Inc. will report earnings per share of $0.8 when they are scheduled to next report results on or around 2015-07-28. Merck shares have tumbled 4.98% over the last three months. Pfizer has a 1-year low of $27.51 and a 1-year high of $35.53. The stock was sold at an average price of $34.39, for a total transaction of $894,140.00.
Advertisement
The price to earnings ratio, or the valuation ratio of a company’s current share price compared to its per-share earnings sits at 14.857. The company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.80 by $0.06, MarketBeat reports. Pfizer’s quarterly revenue was down 7.2% compared to the same quarter past year. Analysts expect that Merck & Co., Inc. will post $3.45 EPS for the current fiscal year. At last check, the security was up 0.6% at $57.35, after earlier bouncing from $56 – an area that contained pullbacks in late October and mid-March.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 2nd. This represents a $1.12 annualized dividend and a dividend yield of 3.17%.
Sanofi agreed to pay Regeneron $640 million upfront, and the two companies will invest $1 billion in developing the drug to the proof-of-concept stage, with Sanofi contributing 75% and Regeneron 25% of the total. The ex-dividend date is Wednesday, August 5th.
Separately, TheStreet Ratings team rates MERCK & CO as a Buy with a ratings score of B+. Vetr raised shares of Pfizer from a “buy” rating to a “strong-buy” rating and set a $45.00 target price on the stock in a research note on Tuesday, July 7th. Zacks cut Merck & Co. from a buy rating to a hold evaluation in a research report on Thursday, July 16th. They issued an “overweight” rating and a $45.00 price target on the stock. Piper Jaffray began coverage on Merck & Co.in a research report on Wednesday, June 17th. Plus, 63% of analysts still maintain a “hold” or “strong sell” rating on Pfizer Inc. The company now has an average rating of “Buy” and a consensus price target of $38.72. Also, EVP Adam H. The deal was disclosed in a filing with the Securities & Trade Commission, which is accessible through the SEC website. Schechter offered 10,634 shares of the corporation’s inventory in a transaction that occurred on Monday, May Possibly 11th. The stock was sold at an average price of $60.44, for a total value of $642,718.96. The disclosure for this sale can be found here.
Advertisement
Health solutions are delivered by the Company through biologic treatments, vaccines, its prescription medicines, animal well-being, and consumer care products, which it markets directly and through its joint ventures. The Companys operations are comprised of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. The Organization has animal health procedures that discover, develop, market and manufacture animal health products. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare.
